Haleon (NYSE:HLN) Issues Earnings Results, Misses Expectations By $0.13 EPS

Haleon (NYSE:HLN) announced its quarterly earnings data on Wednesday. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.27 by ($0.13), FiscalAI reports. The business had revenue of $3.71 billion for the quarter, compared to analyst estimates of $7.43 billion.

Haleon Price Performance

Shares of Haleon stock traded down $0.17 during trading on Thursday, hitting $10.11. 16,090,150 shares of the stock traded hands, compared to its average volume of 9,072,160. The stock has a market cap of $44.51 billion, a price-to-earnings ratio of 25.91, a PEG ratio of 2.37 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. Haleon has a 52 week low of $8.65 and a 52 week high of $11.28. The firm’s fifty day moving average is $9.41 and its 200-day moving average is $9.85.

Wall Street Analyst Weigh In

HLN has been the topic of a number of recent research reports. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a research note on Tuesday, June 30th. Wall Street Zen upgraded shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Rothschild & Co Redburn lowered Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Finally, Zacks Research cut Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Two analysts have rated the stock with a Strong Buy rating, three have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy”.

Institutional Trading of Haleon

Several hedge funds have recently added to or reduced their stakes in the business. Parkside Financial Bank & Trust boosted its holdings in shares of Haleon by 101.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock worth $29,000 after purchasing an additional 1,433 shares during the period. Geneos Wealth Management Inc. increased its holdings in Haleon by 33.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock valued at $50,000 after purchasing an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd increased its holdings in Haleon by 428.1% during the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock valued at $57,000 after purchasing an additional 5,124 shares during the period. Cary Street Partners Financial LLC raised its position in Haleon by 20.1% during the 2nd quarter. Cary Street Partners Financial LLC now owns 6,646 shares of the company’s stock valued at $69,000 after purchasing an additional 1,113 shares during the last quarter. Finally, McMillan Office Inc. bought a new position in Haleon during the 4th quarter valued at approximately $92,000. 6.67% of the stock is owned by institutional investors.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.